CMC Biologics Expands Denmark Facility

May 20, 2015
Pharmaceutical Technology Editors

PTSM: Pharmaceutical Technology Sourcing and Management

PTSM: Pharmaceutical Technology Sourcing and Management-06-03-2015, Volume 11, Issue 6

The Denmark facility will incorporate CMC’s Bioreactor 6Pack configuration in one manufacturing line.

 

CMC Biologics announced that it is expanding its Copenhagen, Denmark facility to increase its manufacturing capacity through the installation of six 2000-L bioreactors. The bioreactors can be run singly or in groups, simultaneously or sequentially, and are part of the company’s signature Bioreactor 6Pack single-use program.

"CMC Biologics is significantly investing in innovative facility design to address our customers' need for production flexibility, to meet aggressive regulatory and production timelines, and to speed their products to market," said Gustavo Mahler, PhD, global chief operations officer of CMC Biologics, in a press release.

The Copenhagen installation will begin initial GMP production in November 2015 and will feature three bioreactors to start. Three bioreactors will be added at a later date to complete the configuration. Meanwhile, the Bioreactor 6Pack at CMC’s Seattle facility will complete its first GMP run in mid-2015 and will be ready for commercial launch by the end of the year. Through its recent expansions, CMC plans to expand its global capacity by more than 30,000 liters in the United States and Europe.

Source:
PR Newswire